Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription 02.06.2025 2 BMC Neurol 1 Curr Opin Immunol 4 J Autoimmun 1 J Clin Endocrinol Metab 2 J Neuroimmunol 5 J Neurol 4 J Pediatr Endocrinol Metab 5 Mult Scler 1 N Engl J Med 1 Nat Rev Neurol 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. HANSEL M, Kalimeris S, Schreiner B, Friedl S, et al
   Cytomegalovirus primo-infection in Guillain-Barre syndrome during pregnancy, a case report of a very serious and rare case.
   BMC Neurol. 2025;25:224.
   PubMed         Abstract available
   
   
2. YOON S, Kim DY, Chu MK
   Nitrous oxide abuse unmasking anti-phospholipid syndrome in a 24-year-old male with cerebral venous thrombosis and pulmonary thromboembolism: a case report.
   BMC Neurol. 2025;25:220.
   PubMed         Abstract available
   
   

   
   Curr Opin Immunol

3. KOLEV M, Kremer AE, Sokollik C, Gershwin ME, et al
   Unmet needs in autoimmune liver diseases.
   Curr Opin Immunol. 2025;95:102565.
   PubMed         Abstract available
   
   

   
   J Autoimmun

4. HOCAOGLU M, Sawalha AH
   Integrated analysis of polygenic and environmental risk scores for late-onset systemic lupus erythematosus.
   J Autoimmun. 2025;154:103441.
   PubMed         Abstract available
   
   
5. VAN DOOREN HJ, Atisha-Fregoso Y, Dorjee AL, Huizinga TWJ, et al
   Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus.
   J Autoimmun. 2025;154:103438.
   PubMed         Abstract available
   
   
6. LEE S, Jo AR, Kim Y, Lee W, et al
   Association between occupational and environmental dust exposure and autoimmune diseases: A systematic review and meta-analysis.
   J Autoimmun. 2025;154:103440.
   PubMed         Abstract available
   
   
7. MAZZUCATO-PUCHNER A, Ramspeck H, Ritschl V, Stamm T, et al
   Passive maternal immunity in children born to women with systemic autoimmune rheumatic disease - A case-control study.
   J Autoimmun. 2025;154:103439.
   PubMed         Abstract available
   
   

   
   J Clin Endocrinol Metab

8. KAEWKRASAESIN C, Hwang M, Vasandani C, Brown RJ, et al
   Clinical features, metabolic and autoimmune derangements in acquired partial lipodystrophy (Barraquer-Simons Syndrome).
   J Clin Endocrinol Metab. 2025 May 28:dgaf315. doi: 10.1210.
   PubMed         Abstract available
   
   

   
   J Neuroimmunol

9. WEIGEL J, Appeltshauser L, Sommer C, Doppler K, et al
   Proprioceptive endings at muscle spindles as a possible target of autoantibodies.
   J Neuroimmunol. 2025;405:578648.
   PubMed         Abstract available
   
   
10. YAO ZY
    Reflections on the influence of seasonal and environmental factors in myasthenia gravis.
    J Neuroimmunol. 2025;405:578645.
    PubMed        
    
    

    
    J Neurol

11. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
    Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
    J Neurol. 2025;272:423.
    PubMed        
    
    
12. PIGNOLO A, Vinciguerra C, Monastero R, Rini N, et al
    Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review.
    J Neurol. 2025;272:417.
    PubMed         Abstract available
    
    
13. GIOFRE F, Lugaresi A, Baccari F, Lui E, et al
    The topography of infratentorial lesions in depression and anxiety in multiple sclerosis.
    J Neurol. 2025;272:420.
    PubMed         Abstract available
    
    
14. ARZALLUZ-LUQUE J, Dumez P, Picard G, Benaiteau M, et al
    Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.
    J Neurol. 2025;272:421.
    PubMed         Abstract available
    
    
15. GASPERINI C, Centonze D, Conte A, Gallo P, et al
    Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
    J Neurol. 2025;272:428.
    PubMed         Abstract available
    
    

    
    J Pediatr Endocrinol Metab

16. UNAL UZUN O, Enes D, Cinar M, Gunlemez Adugit A, et al
    Cord blood metabolomic profiling in high risk newborns born to diabetic, obese, and overweight mothers: preliminary report.
    J Pediatr Endocrinol Metab. 2025;38:577-589.
    PubMed         Abstract available
    
    
17. MATTER RM, Amin GE, Youssef NR, Fereig YA, et al
    Impact of Covid-19 on children and adolescents with type 1 diabetes: lifestyle, telecommunication service, and quality of life.
    J Pediatr Endocrinol Metab. 2025;38:590-598.
    PubMed         Abstract available
    
    
18. BOUSSAID S, Rekik S, Ferjani HL, Abbes M, et al
    Pubertal disorders in juvenile idiopathic arthritis: a systemic review.
    J Pediatr Endocrinol Metab. 2025;38:551-561.
    PubMed         Abstract available
    
    
19. KRNIC N, Braovac D, Vinkovic M, Petrinovic Doresic J, et al
    Diabetes, macrocytosis, and skin changes in large-scale mtDNA deletion.
    J Pediatr Endocrinol Metab. 2025;38:663-667.
    PubMed         Abstract available
    
    

    
    Mult Scler

20. VILASECA A, Vidal-Jordana A, Sceppacuercia S, Calderon W, et al
    Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?
    Mult Scler. 2025 May 30:13524585251332115. doi: 10.1177/13524585251332115.
    PubMed         Abstract available
    
    
21. FOONG YC, Butzkueven H
    Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? - No.
    Mult Scler. 2025 May 26:13524585251344805. doi: 10.1177/13524585251344805.
    PubMed        
    
    
22. ROD BE, Hogestol EA, Torkildsen O, Bjornevik K, et al
    Comparative effectiveness of rituximab and cladribine in relapsing-remitting multiple sclerosis: A target trial emulation.
    Mult Scler. 2025 May 26:13524585251342727. doi: 10.1177/13524585251342727.
    PubMed         Abstract available
    
    
23. ROSTON S, Quick MH, Tisavipat N, Rattanathamsakul N, et al
    Assessment of increased opening pressure in patients with multiple sclerosis and aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder.
    Mult Scler. 2025 May 26:13524585251340841. doi: 10.1177/13524585251340841.
    PubMed         Abstract available
    
    
24. ZANE GK, Sutton A, Brumwell A, Hossain MR, et al
    The path to prevention of multiple sclerosis: Considerations for Epstein-Barr virus vaccine-based prevention studies.
    Mult Scler. 2025 May 26:13524585251340812. doi: 10.1177/13524585251340812.
    PubMed         Abstract available
    
    

    
    N Engl J Med

25. KOSTER MJ, Warrington KJ
    Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis.
    N Engl J Med. 2025;392:2062-2064.
    PubMed        
    
    

    
    Nat Rev Neurol

26. LANGER-GOULD AM, Cepon-Robins TJ, Benn Torres J, Yeh EA, et al
    Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA.
    Nat Rev Neurol. 2025 May 27. doi: 10.1038/s41582-025-01096.
    PubMed         Abstract available
    
    

    
    PLoS One

27. KRULL F, Hosseini S, Bleyer M, Brenig B, et al
    Findings from transcriptomics and immunohistochemistry indicate an autoimmune disease targeting brainstem inhibitory interneurons in bovine spastic paresis.
    PLoS One. 2025;20:e0324633.
    PubMed         Abstract available
    
    
28. MAKHLOUF Y, Ayed HB, Miladi S, Boussaa H, et al
    Effect of biologic treatments on growth in children with juvenile idiopathic arthritis: A systematic review.
    PLoS One. 2025;20:e0324440.
    PubMed         Abstract available
    
    
29. RAINA M, Shah R, Hu J, Pember B, et al
    The global health burden of pediatric chronic kidney disease: An analysis of the Global Burden of Disease database from 1990 to 2021.
    PLoS One. 2025;20:e0323257.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.